Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Dicerna Pharmaceutic (NQ: DRNA )

26.62 USD -0.78 (-2.85%)
Official Closing Price Updated: 5:39 PM EST, Mar 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 711,202
Open 28.18
Bid (Size) 25.98 (1)
Ask (Size) 30.00 (2)
Prev. Close 27.40
Today's Range 26.41 - 28.25
52wk Range 11.75 - 29.90
Shares Outstanding 52,821,624
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection
Dicerna today announced that Roche has initiated RG6346 in the Roche sponsored Phase 2 combination trial for the treatment of chronic HBV infection. 
From Business Wire News Releases
Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update
Dicerna today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update. 
From Business Wire News Releases

Performance

YTD
+20.62%
+20.62%
1 Month
-5.37%
-5.37%
3 Month
+8.88%
+8.88%
6 Month
+53.52%
+53.52%
1 Year
+42.96%
+42.96%

More News

Read More
Dicerna to Participate in Upcoming Investor Conferences
From Business Wire News Releases
Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021
From Business Wire News Releases
Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3
From Business Wire News Releases
Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference
From Business Wire News Releases
Recap: Dicerna Pharmaceuticals Q4 Earnings
Tags Market News DRNA Earnings
From Benzinga
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
From Business Wire News Releases
Dicerna Pharmaceuticals Shows Rising Relative Price Performance; Still Shy Of Key Threshold
From Investor's Business Daily
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Business Wire News Releases
Dicerna Pharmaceuticals Inc (DRNA) Q4 2020 Earnings Call Transcript
Tags Market News DRNA
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.